{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:59:42Z","timestamp":1782791982123,"version":"3.54.5"},"reference-count":92,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Over recent decades, an improved understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) and glucose regulation has led to innovative research and new treatment paradigms. The discovery of the gut peptide glucagon-like peptide-1 (GLP-1) and its role in glucose regulation paved the way for the class of GLP-1 receptor agonist compounds, or GLP-1RAs. The long-acting GLP-1RAs (dulaglutide, exenatide extended-release, liraglutide, semaglutide [injectable and oral]) are classified as such based on a minimum 24-hour duration of clinically relevant effects after administration. In phase 3 clinical trial programs of long-acting GLP-1RAs, A1C typically was reduced in the range of 1% to 1.5%, with reductions close to 2% in some studies. GLP-1RAs when used alone (without sulfonylureas or insulin) have a low risk of hypoglycemia because, like endogenous GLP-1, their insulinotropic effects are glucose-dependent. In addition to local actions in the gastrointestinal (GI) tract, GLP-1RAs stimulate receptors in the central nervous system to increase satiety, resulting in weight loss. All long-acting GLP-1RAs have, at minimum, been shown to be safe and not increase cardiovascular (CV) risk and most (liraglutide, semaglutide injectable, dulaglutide, albiglutide) have been shown in CV outcomes trials (CVOTs) to significantly reduce the risk of major cardiac adverse events. The class has good tolerability overall, with generally transient GI adverse events being most common. The weekly injectable agents offer scheduling convenience and may promote treatment adherence. One long-acting GLP-1RA is available as an oral daily tablet, which may be preferable for some patients and providers.<\/jats:p>","DOI":"10.1097\/01.jaa.0000669456.13763.bd","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T22:00:26Z","timestamp":1596060026000},"page":"3-18","source":"Crossref","is-referenced-by-count":42,"title":["Long-acting GLP-1RAs"],"prefix":"10.1097","volume":"33","author":[{"given":"Ji Hyun","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Butts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"9-a suppl","key":"R1-20230817","first-page":"S5","article-title":"Burden of illness in type 2 diabetes mellitus","volume":"24","author":"Cannon","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"suppl 1","key":"R3-20230817","article-title":"Global prevalence of type 2 diabetes over the next ten years (2018-2028)","volume":"67","author":"Bradshaw Kaiser","year":"2018","journal-title":"Diabetes"},{"issue":"2","key":"R4-20230817","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/jdi.12911","article-title":"Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development","volume":"10","author":"Ahr\u00e9n","year":"2019","journal-title":"J Diabetes Investig"},{"key":"R5-20230817","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2019.00260","article-title":"From the incretin concept and the discovery of GLP-1 to today's diabetes therapy","volume":"10","author":"Holst","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"R6-20230817","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J Clin Invest"},{"issue":"4","key":"R7-20230817","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"issue":"suppl 2","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.2337\/dcS13-2011","article-title":"Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"R9-20230817","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"R10-20230817","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1460863","article-title":"The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects","volume":"146","author":"Hui","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"9309","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"R12-20230817","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"R13-20230817","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.toxicon.2010.12.016","article-title":"The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent","volume":"59","author":"Furman","year":"2012","journal-title":"Toxicon"},{"issue":"8","key":"R14-20230817","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes: their use and differential features","volume":"39","author":"Lyseng-Williamson","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"5","key":"R15-20230817","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/atm.2019.01.09","article-title":"Long-acting glucagon-like peptide-1 receptor agonist\u2014Status December 2018","volume":"7","author":"Holst","year":"2019","journal-title":"Ann Transl Med"},{"key":"R16-20230817","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13098-017-0204-6","article-title":"Is there a justification for classifying GLP-1 receptor agonists as basal and prandial","volume":"9","author":"Mi\u00f1ambres","year":"2017","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"R17-20230817","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"R18-20230817","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2042018815580257","article-title":"Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance","volume":"6","author":"Tella","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"8","key":"R26-20230817","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"9645","key":"R27-20230817","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"R28-20230817","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9683","key":"R29-20230817","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"R30-20230817","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"issue":"1","key":"R31-20230817","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"7","key":"R32-20230817","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"R33-20230817","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"9662","key":"R34-20230817","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"R35-20230817","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/dom.12012","article-title":"Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study","volume":"15","author":"Nauck","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"R36-20230817","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","article-title":"Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes","volume":"13","author":"Garber","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"9739","key":"R37-20230817","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"issue":"9733","key":"R38-20230817","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"R39-20230817","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"issue":"9861","key":"R40-20230817","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"R41-20230817","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/dom.13266","article-title":"Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study","volume":"20","author":"Guja","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"R42-20230817","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"R43-20230817","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.mayocp.2015.01.008","article-title":"Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial","volume":"90","author":"Wysham","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"R44-20230817","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"issue":"9982","key":"R45-20230817","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"issue":"9951","key":"R46-20230817","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"R47-20230817","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/dom.12634","article-title":"A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)","volume":"18","author":"Dungan","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"R48-20230817","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"R49-20230817","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"R50-20230817","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"R51-20230817","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"R52-20230817","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"R53-20230817","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"R54-20230817","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"R55-20230817","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"R56-20230817","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"R57-20230817","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"R58-20230817","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R59-20230817","doi-asserted-by":"crossref","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"issue":"10192","key":"R60-20230817","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"R61-20230817","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"R62-20230817","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"15","key":"R63-20230817","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"R65-20230817","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"R66-20230817","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/obr.12841","article-title":"Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities","volume":"20","author":"Brown","year":"2019","journal-title":"Obes Rev"},{"issue":"24","key":"R68-20230817","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"9739","key":"R69-20230817","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"R70-20230817","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"R71-20230817","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"R73-20230817","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"R74-20230817","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"R75-20230817","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10157","key":"R76-20230817","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"R77-20230817","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"R78-20230817","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"R80-20230817","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"R81-20230817","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"issue":"2","key":"R82-20230817","first-page":"227","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues","volume":"16","author":"Raccah","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"R83-20230817","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"R85-20230817","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"R86-20230817","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"R87-20230817","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"R88-20230817","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"R89-20230817","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"Filippatos","year":"2013","journal-title":"World J Diabetes"},{"issue":"11","key":"R90-20230817","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00592-017-1049-z","article-title":"Erratum to: Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"54","author":"Dicembrini","year":"2017","journal-title":"Acta Diabetol"},{"issue":"11","key":"R91-20230817","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2337\/dc17-2280","article-title":"Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy","volume":"41","author":"Douros","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"R92-20230817","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.13484","article-title":"Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis","volume":"21","author":"Avgerinos","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"R93-20230817","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.2337\/dc17-2285","article-title":"Incretin-based therapies and diabetic retinopathy: real-world evidence in older U.S. adults","volume":"41","author":"Wang","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"R94-20230817","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metab"},{"issue":"3","key":"R95-20230817","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"R96-20230817","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"issue":"8","key":"R97-20230817","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.clinthera.2015.05.505","article-title":"Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy","volume":"37","author":"Iglay","year":"2015","journal-title":"Clin Ther"},{"key":"R98-20230817","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11657-015-0231-6","article-title":"Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA","volume":"10","author":"Kishimoto","year":"2015","journal-title":"Arch Osteoporos"},{"issue":"2","key":"R99-20230817","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13300-017-0230-2","article-title":"Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-na\u00efve patients with type 2 diabetes mellitus: a multinational preference study","volume":"8","author":"Qin","year":"2017","journal-title":"Diabetes Ther"},{"issue":"11","key":"R100-20230817","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s12325-014-0166-0","article-title":"Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States","volume":"31","author":"Johnston","year":"2014","journal-title":"Adv Ther"},{"issue":"3","key":"R101-20230817","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Adv Ther"},{"key":"R102-20230817","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/DMSO.S99732","article-title":"Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany","volume":"9","author":"Qiao","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"7","key":"R103-20230817","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/dom.12902","article-title":"Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide","volume":"19","author":"Alatorre","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"R104-20230817","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/CS-2018-0535","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142019 executive summary","volume":"25","author":"Garber","year":"2019","journal-title":"Endocr Pract"},{"issue":"24","key":"R105-20230817","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000669456.13763.bd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:16:38Z","timestamp":1692321398000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000669456.13763.bd"}},"subtitle":["An overview of efficacy, safety, and their role in type 2 diabetes management"],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":92,"journal-issue":{"issue":"S8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000669456.13763.bd","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}